297 related articles for article (PubMed ID: 20169078)
1. Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR.
Dere R; Wilson PD; Sandford RN; Walker CL
PLoS One; 2010 Feb; 5(2):e9239. PubMed ID: 20169078
[TBL] [Abstract][Full Text] [Related]
2. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
Miyazaki M; McCarthy JJ; Esser KA
FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
[TBL] [Abstract][Full Text] [Related]
3. The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway.
Hartman TR; Liu D; Zilfou JT; Robb V; Morrison T; Watnick T; Henske EP
Hum Mol Genet; 2009 Jan; 18(1):151-63. PubMed ID: 18845692
[TBL] [Abstract][Full Text] [Related]
4. Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1.
Distefano G; Boca M; Rowe I; Wodarczyk C; Ma L; Piontek KB; Germino GG; Pandolfi PP; Boletta A
Mol Cell Biol; 2009 May; 29(9):2359-71. PubMed ID: 19255143
[TBL] [Abstract][Full Text] [Related]
5. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
Lu KH; Wu W; Dave B; Slomovitz BM; Burke TW; Munsell MF; Broaddus RR; Walker CL
Clin Cancer Res; 2008 May; 14(9):2543-50. PubMed ID: 18451215
[TBL] [Abstract][Full Text] [Related]
6. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity.
Hahn-Windgassen A; Nogueira V; Chen CC; Skeen JE; Sonenberg N; Hay N
J Biol Chem; 2005 Sep; 280(37):32081-9. PubMed ID: 16027121
[TBL] [Abstract][Full Text] [Related]
7. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses.
Smith EM; Finn SG; Tee AR; Browne GJ; Proud CG
J Biol Chem; 2005 May; 280(19):18717-27. PubMed ID: 15772076
[TBL] [Abstract][Full Text] [Related]
8. Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease.
Qin S; Taglienti M; Nauli SM; Contrino L; Takakura A; Zhou J; Kreidberg JA
J Clin Invest; 2010 Oct; 120(10):3617-28. PubMed ID: 20852388
[TBL] [Abstract][Full Text] [Related]
9. Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated.
Cabrera-López C; Bullich G; Martí T; Català V; Ballarín J; Bissler JJ; Harris PC; Ars E; Torra R
BMC Med Genet; 2015 Jun; 16():39. PubMed ID: 26077033
[TBL] [Abstract][Full Text] [Related]
10. REDD2 is enriched in skeletal muscle and inhibits mTOR signaling in response to leucine and stretch.
Miyazaki M; Esser KA
Am J Physiol Cell Physiol; 2009 Mar; 296(3):C583-92. PubMed ID: 19129461
[TBL] [Abstract][Full Text] [Related]
11. A complex interplay between Akt, TSC2 and the two mTOR complexes.
Huang J; Manning BD
Biochem Soc Trans; 2009 Feb; 37(Pt 1):217-22. PubMed ID: 19143635
[TBL] [Abstract][Full Text] [Related]
12. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions.
Matthew EM; Hart LS; Astrinidis A; Navaraj A; Dolloff NG; Dicker DT; Henske EP; El-Deiry WS
Cell Cycle; 2009 Dec; 8(24):4168-75. PubMed ID: 20054236
[TBL] [Abstract][Full Text] [Related]
13. Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin.
Mekahli D; Decuypere JP; Sammels E; Welkenhuyzen K; Schoeber J; Audrezet MP; Corvelyn A; Dechênes G; Ong AC; Wilmer MJ; van den Heuvel L; Bultynck G; Parys JB; Missiaen L; Levtchenko E; De Smedt H
Pflugers Arch; 2014 Aug; 466(8):1591-604. PubMed ID: 24193408
[TBL] [Abstract][Full Text] [Related]
14. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
15. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2.
Huang J; Dibble CC; Matsuzaki M; Manning BD
Mol Cell Biol; 2008 Jun; 28(12):4104-15. PubMed ID: 18411301
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation, protein kinases and ADPKD.
Li X
Biochim Biophys Acta; 2011 Oct; 1812(10):1219-24. PubMed ID: 21392577
[TBL] [Abstract][Full Text] [Related]
17. The heteromeric PC-1/PC-2 polycystin complex is activated by the PC-1 N-terminus.
Ha K; Nobuhara M; Wang Q; Walker RV; Qian F; Schartner C; Cao E; Delling M
Elife; 2020 Nov; 9():. PubMed ID: 33164752
[TBL] [Abstract][Full Text] [Related]
18. Concurrent Reduced Expression of Contiguous
Meguro S; Koguchi T; Hakozaki Y; Onagi A; Matsuoka K; Hoshi S; Hata J; Sato Y; Akaihata H; Kataoka M; Ogawa S; Kojima Y
Cancer Genomics Proteomics; 2023; 20(1):40-50. PubMed ID: 36581342
[TBL] [Abstract][Full Text] [Related]
19. Divergent function of polycystin 1 and polycystin 2 in cell size regulation.
Viau A; Kotsis F; Boehlke C; Braeg S; Klein M; Nitschke R; Walz G; Kuehn EW
Biochem Biophys Res Commun; 2020 Jan; 521(2):290-295. PubMed ID: 31668373
[TBL] [Abstract][Full Text] [Related]
20. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Mancini M; Petta S; Martinelli G; Barbieri E; Santucci MA
J Cell Biochem; 2010 Feb; 109(2):320-8. PubMed ID: 20014066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
